ALAng Li

Ang Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ang Li has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dissecting Novel Tumor Antigens and Immune Subtypes Guided mRNA Vaccine Development for HBV Related-Hepatocellular Carcinoma

    by Ang Li, Bicheng Ye, Fangnan Lin, Peiwen Zhou, Yilin Wang, Xiaye Miao, Yanfang Jiang

    The mRNA vaccines are considered to be effective treatment strategies for cancers, but its progress in chronic hepatitis B virus (HBV) related-hepatocellular carcinoma (HCC) was slow. This study aimed to find potential antigens and identify suitable patients in HBV related-HCC for guiding mRNA vaccine development. We integrated the transcriptome RNA expression matrices and somatic mutation data from TCGA and ICGC datasets. A consistency matrix was constructed by using ConsensusClusterPlus to identify the immune subtypes. Graph learning based dimensional reduction was analyzed to establish immune landscape. Four upregulated and mutated antigens (EPS8L3, TCOF1, EZH2, and NOP56) were highly correlated with unfavorable clinical outcomes and antigen presenting cells (APCs). And two distinct immune phenotypes with differential clinical, cellular, and molecular characteristics were identified by in the ICGC and TCGA cohorts. IS1 is immune “hot” and immunosuppressive phenotype, with low tumor mutation burden (TMB) and high immune checkpoints (ICPs). On the contrary, IS2 is immune “cold” phenotype with high TMB and low ICPs. Monocle3 package was used to further study the intra-cluster heterogeneity, which identified cluster IS2A/2B within IS2 subtype was determined to be more suitable for mRNA vaccine. In summary, EPS8L3, TCOF1, EZH2, and NOP56 are potential antigens for mRNA vaccine development against HBV related-HCC, and patients in IS2A/2B are relatively more suitable for vaccination.


  • Open Access

    Development and Validation of a Novel Glycolysis-Related Risk Signature for Predicting Survival in Pancreatic Adenocarcinoma

    by Ang Li, Sinan Hou, Jian Chen, Huimin Hou, Yanfang Jiang

    Background Pancreatic adenocarcinoma (PAAD) is one of the leading causes of cancer death worldwide. Through data mining, an increasing number of biomarkers have been identified for predicting survival of PAAD. However, the ability of single gene biomarkers to predict patient survival is still insufficient. This study aimed to develop a novel risk signature for predicting survival of PAAD. Methods mRNA expression profiling was performed in a large PAAD cohort (N = 177) from The Cancer Genome Atlas (TCGA) database. Gene Set Enrichment Analysis (GSEA) was analyzed to detect whether the gene sets showed statistically differences between PAAD and adjacent normal tissues. Univariate Cox regression analysis was used to analyze and identify genes related to overall survival (OS), then subjected to multivariable Cox regression to further confirm the prognostic genes and obtain the coefficients. The expression level of selected genes weighted by their coefficients through linearly combining, we constructed a risk score formula for prognostic prediction. The three-mRNA signature for survival prediction is validated by Kaplan–Meier curve analysis. Results We demonstrated that a set of three genes (KIF20A, CHST2, and MET) were significantly associated with OS. Based on this three-gene signature, 177 PAAD patients were classified into high-risk groups and low-risk groups using the median risk score as cut off value. Additionally, multivariate Cox regression analysis revealed that the three-gene signature had independent prognostic value. Conclusions To our best knowledge, we first develop a glycolysis-related risk signature for predicting survival of pancreatic adenocarcinoma. The findings provide insight into identification of patients with poor prognosis in PAAD and improve novel therapy targets for this disease.

  • Abstract 4939: Alteration of TGFB signaling pathway predicts worse prognosis in pancreatic ductal adenocarcinoma

    by Mao Li, Ang Li, Xiaochen Zhao, Shengzhong Hou, Shan Lu, Yu Mou, Xubao Liu, Dan Cao, Shangli Cai, Bole Tian

    Background: For pancreatic ductal adenocarcinoma (PDAC), a reliable and practical prognostic biomarker is still in unmet needs. Transforming growth factor beta (TGFB) signaling pathway is one of the core pathways involved in tumor initiation and progression via canonical and non-canonical pathway. The prognostic value of TGFB pathway genes as a functionally related group in PDAC is rarely studied.Methods: 72 PDAC patients who underwent surgery between November 30, 2015 and September 13, 2017 in West China Hospital, Sichuan University were identified and included in this study. Whole-exome sequencing (WES) or targeted next-generation sequencing was performed with tumor tissue from primary tumors. Clinical data was retrospectively collected. Clinicopathologic characteristics and overall survival were analyzed.Results: Genetic alterations were detected in 70 patients (97.2%). While 1 patient (1.4%) had only one genetic alteration, 28 patients (38.9%) had 2-4 genetic alterations and 43 patients (59.7%) had ≥5 genetic alterations. Overall, 25 patients (34.7%) with alteration of TGFB pathway and 47 patients (65.3%) with wild type of TGFB pathway were identified as TGFBm+ group and TGFBm- group respectively. TGFBm+ group had worse overall survival (HR, 1.875, 95% CI: 1.06-4.72; P = 0.04), especially in patients who had radical surgery (HR, 3.11, 95% CI: 1.11-20.3; P = 0.04). While in the subgroup of patients who underwent palliative surgery, OS was not statistically different (HR, 0.93, 95% CI: 0.42-2.04; P = 0.85). Subgroup analysis showed that overall survival hazard ratio favored participants with wild type of TGFB pathway in patients with ECOG performance score >1, abnormal CA199, without metastasis, stage I to II and patients who accepted radical surgery.Conclusion: Alteration of TGFB pathway genes is prevalent in PDAC. Inferior prognosis was observed in PDACs with mutations of TGFB pathway. TGFB signaling might play different role in different tumor stages, which is consistent with previous report about paradoxical effect of TGFB pathway. Genomic sequencing could help screen out patients at risk after surgery and adjuvant therapy might benefit this subgroup of PDACs. Note: This abstract was not presented at the meeting. Citation Format: Mao Li, Ang Li, Xiaochen Zhao, Shengzhong Hou, Shan Lu, Yu Mou, Xubao Liu, Dan Cao, Shangli Cai, Bole Tian. Alteration of TGFB signaling pathway predicts worse prognosis in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4939.

  • Open Access

    Hyaline vascular variant of unicentric Castleman disease of the tonsil: a case report

    by Ping Li, Huaipu Liu, Hao Li, Ang Li, Guangyin Yu, Weihua Yin

    Castleman disease (CD) is a lymphoproliferative disorder with an unknown etiology. The disease may be unicentric (UCD) or multicentric (MCD), and three histopathologic variants have been described: hyaline vascular (HV), plasma cell (PC), and mixed type. Extranodal CD is rare. Herein, we report a case of CD presenting as a tonsillar mass, which has not been documented in the literature. The patient was a 32-year-old man. Laryngoscopy revealed tonsillar hypertrophy, and the patient underwent a low-temperature plasma tonsillectomy. Microscopic examination of permanent sections showed lymphoid follicular hyperplasia, a portion of which appeared to be a fusion of nodular hyperplasia (composed of lymphoid follicles of variable size and shape). These distinctive follicles with atrophic hyalinized germinal centers and a broad mantle zone of small lymphocytes formed concentric rings (so-called onion-skin arrangement). Medium-sized vessels and a plethora of capillaries were present in the center of the lymphatic follicles, mantle zones, and interfollicular areas. A characteristic lollipop appearance was also observed due to the onion-skin arrangement of the expanded mantle zone lymphocytes with a vessel penetrating the germinal center. No aberrant lymphoid population was present based on CD3, CD5, CD20, CD79α, CD21, CD23, bcl-2, cyclin D1, and ki-67 immunostaining. Tests for human herpesvirus (HHV)-8 and Epstein Barr virus (EBV)-encoded small RNA (EBER) were negative. Therefore, a diagnosis of an HV variant UCD was rendered. The patient was treated by local excision without any other therapy based on the diagnosis. At the 7-month follow up, the patient had no recurrent symptoms or masses. We present an unusual case of a tonsil presenting hyaline vascular Castleman disease (HVCD). This study aims to highlight CD as a differential diagnosis that should be considered by otolaryngologists and pathologists for lymphoproliferative disorders of the tonsil.